← Eichor
Study identifier: NCT06605755 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants

Condition: Pertussis · Diphtheria · Tetanus  ·  Sponsor: Jiangsu Province Centers for Disease Control and Prevention

PhaseNA
Planned participants785
Who can joinAll sexes, 19 Months to 22 Months
Healthy volunteersYes

About this study

The main purpose of this study is to evaluate immune persistence at 30 and 36 Months of Age and Pertussis Breakthrough Infections between 19 and 36 Months of Age following two regiments of DTaP-IPV/Hib Pentavalent Vaccine in Healthy 2-Month-Old Infants and Children in China.

This description comes directly from the study's public registry record.

Talk to the study team

Jingxin Li  ·  +8613813865838  ·  jingxin42102209@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Jingsu Provincial Centre of Disease Control and PreventionNanjing, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06605755